T

hey’re known colloquially as “suicide headaches,” because the pain can be so severe that people who suffer from them take their own lives at a disproportionately high rate.

Cluster headaches, as the rare condition is known, are characterized by bursts of severe pain in cyclical patterns. They’re often misdiagnosed and undertreated. But on Tuesday, the Food and Drug Administration cleared a new, first-of-its kind option for such patients: a handheld device, designed to be used by patients to zap their own necks with a mild electrical signal to relieve symptoms.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy